Not sure who they buyer will be could be anyone now that Rytary is performing so well!
Board size just approved with 2 less, ready for a sale, I think MNK should step up and do it!!
I am in and holding!!
IPXL is the best mid size generic company available with strong prospects that include recent Adderal XR approval and Generic Oxycontin to be approved once and for all. With the huge pull back in the sector this one is the most valuable with a Proprietary Arm of Rytary for Parkinsons and Zomig for Headaches. Rytary is a 88% margin earner and sales are estimated to reach $350-400 mil US and they recently recieved approval in Europe!!
Approvals like adderal xr and rytary parkinsons drug starting to sell nicely about to hit the european market, 10 years of rytary at 88% margin for long acting parkinsons drug, someone will snap up ipxl, mnk should do it now for $3.5 billion small purchase huge returns including bolstering pipeline
Check it out, every knew things were slowing but this is beyond punishment and the fund managers are getting easy pickings here! ENDP going to pop $5 to $20 and hold there
Will happen fast so check it out!
The shares were depressed in the $20's and everyone knew it. now it is ready to climb and is starting to roll!
Time to buy for a quick pop!
It will happen quickly, looking for a 5 point pop to par $20/Share ENDP
IPXL is knocking the cover off the ball and is the best available generic to be had by a big! They are throwing off $80 mil per quarter in free cash flow and Rytary sales just starting to ramp 88% margins with a potential yearly revenue target of $350-400 mil in the US. They have recently been approved in Europe for Rytary to treat Parkinsons and will hold 10 years of shelf exclusivity.. Huge pipline, Adderal XR recently approved and launched and Renvella coming soon with Generic Oxycontin. Revenus to explode well north of $1 billion, awesome value play for a big, perhaps Allergan??
The rumbling is Pfizer or Abbot labs but AGN could very well be a suitor and develop Mylan and sell them off in a few years at double where they are now. Check it out!
The rumor is PFE will by them and consolidate with their legacy business and split it off, tax inversion already in place and successful. Something is coming.... check out MYL $41.5 and climbing quickly!
Management could scoop this one up for $4 billion if they can find the financing, huge pipeline awaiting the right partner!!
They have just relaunched Adderal XR after approval, they have Renvella and generic Oxycontin nearing full approval. Proprietary Rytary for Parkinsons is buidling steam, could be a 88% margin drug witrh 10 years of shelf protection. Annual says targeted at $350-400 mil and compounded if they ink a Euro partner. Drug received full European clearance within a month. They have $400 mil in cash and $400 mil in debt growing immensely!
More supportuning news is the Chairman and CEO of Myl just loaded back up with shares over 1 million a piece in option grants. I hear they wan to exit
These are initial rumblings but they make a lot of sense with the huge pull back in Myl's shares. THE chairman and CEO just reloaded on 1 million shares and they want to exit I hear. Check it out, it's a value-buyout play materializing
The rumble is and has been a buyout of Mylan and then spit of business of Pfizer and Mylan MYL. Look for a $80 bid, it is coming!
TPG added a board member after the retreat and are buying up a majority stake at pennies on the dollar! The sold Par pharma to Endo for $8 billion and now can buy the combined company for less than $4 billion, NO brainer!
I see a deal being inked anyday now! Could be AstraZ to enhance their Sandoz opps!! Biosims the way of the future profit in this space and insurance when things fall off patent!